SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

Jasper Therapeutics, Inc.

(Name of Issuer)

Voting Common Stock, par value $0.0001 per share

(Title of Class of Securities)

(CUSIP Number)

08/17/2026

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

- ☐ Rule 13d-1(b)
- ☑ Rule 13d-1(c)
- ☐ Rule 13d-1(d)

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Velan Capital Master Fund LP	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization CAYMAN ISLANDS	
Number of Shares Beneficially	5	Sole Voting Power 0.00

Owned by Each Reporting Person With:	6	Shared Voting Power 3,037,776.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,037,776.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,037,776.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 8.9 %
12	Type of Reporting Person (See Instructions) PN

Comment for Type of Reporting Person: The Reporting Persons (as defined below) initially filed a Schedule 13G with respect to the securities of the Issuer (as defined below) on October 4, 2021. Subsequently, on February 16, 2023, the Reporting Persons' investment intent changed with respect to the securities of the Issuer and the Reporting Persons filed a Schedule 13D on February 27, 2023 in accordance with Rule 13d-1(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). As of August 17, 2026, the Reporting Persons no longer held securities of the Issuer with a purpose or effect of changing or influencing control of the Issuer, or in connection with or as a participant in any transaction having that purpose or effect. Accordingly, the Reporting Persons are filing this statement on Schedule 13G pursuant to Rule 13d-1(c) of the Exchange Act in accordance with Rule 13d-1(h) of the Exchange Act.

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Velan Capital Holdings LLC
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,037,776.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,037,776.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,037,776.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 8.9 %
12	Type of Reporting Person (See Instructions) OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Velan Horizon Fund LP		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 82,008.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 82,008.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 82,008.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 0.2 %		
12	Type of Reporting Person (See Instructions) PN		

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Velan Horizon GP LLC		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 82,008.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 82,008.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 82,008.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 0.2 %		
12	Type of Reporting Person (See Instructions) OO		

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Avego Healthcare Capital, L.P.		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization DELAWARE		
Number of Shares Beneficially Owned by Each Reporting	5	Sole Voting Power 0.00	
	6	Shared Voting Power	

Person With:		243,563.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 243,563.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 243,563.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.7 %	
12	Type of Reporting Person (See Instructions) PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Avego Healthcare Capital Holdings, LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 243,563.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 243,563.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 243,563.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.7 %	
12	Type of Reporting Person (See Instructions)	

OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Avego Management LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 243,563.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 243,563.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 243,563.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.7 %	
12	Type of Reporting Person (See Instructions) OO	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Velan Capital Investment Management LP
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization

	DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,363,347.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,363,347.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,363,347.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 9.9 %	
12	Type of Reporting Person (See Instructions) PN	

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Velan Capital Management LLC	
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)	
3	Sec Use Only	
4	Citizenship or Place of Organization DELAWARE	
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,363,347.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,363,347.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,363,347.00	

10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 9.9 %
12	Type of Reporting Person (See Instructions) OO

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Morgan Adam		
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)		
3	Sec Use Only		
4	Citizenship or Place of Organization UNITED STATES		
Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00	
	6	Shared Voting Power 3,363,347.00	
	7	Sole Dispositive Power 0.00	
	8	Shared Dispositive Power 3,363,347.00	
9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,363,347.00		
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐		
11	Percent of class represented by amount in row (9) 9.9 %		
12	Type of Reporting Person (See Instructions) IN		

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons

	VENKATARAMAN BALAJI
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 0.00
	6	Shared Voting Power 3,363,347.00
	7	Sole Dispositive Power 0.00
	8	Shared Dispositive Power 3,363,347.00

9	Aggregate Amount Beneficially Owned by Each Reporting Person 3,363,347.00
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐
11	Percent of class represented by amount in row (9) 9.9 %
12	Type of Reporting Person (See Instructions) IN

SCHEDULE 13G

CUSIP No.

1	Names of Reporting Persons Kapoor Vishal
2	Check the appropriate box if a member of a Group (see instructions) ☐ (a) ☐ (b)
3	Sec Use Only
4	Citizenship or Place of Organization UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:	5	Sole Voting Power 35,013.00
	6	Shared Voting Power 0.00
	7	Sole Dispositive Power 35,013.00

	8	Shared Dispositive Power 0.00
9	Aggregate Amount Beneficially Owned by Each Reporting Person 35,013.00	
10	Check box if the aggregate amount in row (9) excludes certain shares (See Instructions) ☐	
11	Percent of class represented by amount in row (9) 0.1 %	
12	Type of Reporting Person (See Instructions) IN	

SCHEDULE 13G

Item 1.

(a) Name of issuer:

Jasper Therapeutics, Inc.

(b) Address of issuer's principal executive offices:

2200 BRIDGE PKWY SUITE #102, REDWOOD CITY, CALIFORNIA , 94065.

Item 2.

(a) Name of person filing:

(i) Velan Capital Master Fund LP, an exempted limited partnership organized under the laws of the Cayman Islands ("Velan Master"), with respect to the shares of voting common stock, par value $0.0001 per share, of the Issuer (the "Shares") directly and beneficially owned by it; (ii) Velan Capital Holdings LLC, a Delaware limited liability company ("Velan GP"), as the general partner of Velan Master; (iii) Velan Horizon Fund LP, a Delaware limited partnership ("Velan Horizon"), with respect to the Shares directly and beneficially owned by it; (iv) Velan Horizon GP LLC, a Delaware limited liability company ("Velan Horizon GP"), as the general partner of Velan Horizon; (v) Avego Healthcare Capital, L.P., a Delaware limited partnership ("Avego Fund"), with respect to the Shares directly and beneficially owned by it; (vi) Avego Healthcare Capital Holdings, LLC, a Delaware limited liability company ("Avego GP"), as the general partner of Avego Fund; (vii) Avego Management, LLC, a Delaware limited liability company ("Avego Management"), as the co-investment manager of Avego Fund; (viii) Velan Capital Investment Management LP, a Delaware limited partnership ("Velan Capital"), as the investment manager of Velan Master and Velan Horizon and co-investment manager of Avego Fund; (ix) Velan Capital Management LLC, a Delaware limited liability company ("Velan IM GP"), as the general partner of Velan Capital; (x) Adam Morgan, as the Chief Investment Officer of Velan Capital and a Managing Member of each of Velan GP, Velan Horizon GP and Velan IM GP; (xi) Balaji Venkataraman, as the Managing Member of each of Avego GP and Avego Management and a Managing Member of each of Velan GP, Velan Horizon GP and Velan IM GP; and (xii) Vishal Kapoor, with respect to the Shares directly and beneficially owned by him. Each of the foregoing is referred to as a "Reporting Person" and collectively as the "Reporting Persons."

(b) Address or principal business office or, if none, residence:

The address of the principal office of Velan Master is 89 Nexus Way, Camana Bay, Grand Cayman KY1-9009, Cayman Islands. The address of the principal office of each of the other Reporting Persons is 100 North Main Street, Suite 301, Alpharetta, Georgia 30009

(c) Citizenship:

Velan Master is organized under the laws of the Cayman Islands. Velan GP, Velan Horizon, Velan Horizon GP, Avego Fund, Avego GP, Avego Management, Velan Capital and Velan IM GP are organized under the laws of the State of Delaware. Messrs. Morgan, Venkataraman and Kapoor are citizens of the United States of America.

(d) Title of class of securities:

Voting Common Stock, par value $0.0001 per share

(e) CUSIP No.:

Item 3. If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:

(a) ☐ Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);

(b) ☐ Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);

(c) ☐ Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);

(d) ☐ Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);

(e) ☐ An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);

(f) ☐ An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);

(g) ☐ A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);

(h) ☐ A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);

(i) ☐ A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);

(j) ☐ A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:

(k) ☐ Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).

Item 4. Ownership

(a) Amount beneficially owned:

As of the date hereof: (i) Velan Master directly beneficially owns 3,037,776 Shares (including 673,000 Shares underlying certain warrants); (ii) Velan GP, as the general partner of Velan Master, may be deemed to beneficially own the 3,037,776 Shares beneficially owned by Velan Master; (iii) Velan Horizon directly beneficially owns 82,008 Shares (including 41,152 Shares underlying certain warrants); (iv) Velan Horizon GP, as the general partner of Velan Horizon, may be deemed to beneficially own the 82,008 Shares beneficially owned by Velan Horizon; (v) Avego Fund directly beneficially owns 243,563 Shares; (vi) Avego GP, as the general partner of Avego Fund, may be deemed to beneficially own the 243,563 Shares beneficially owned by Avego Fund; (vii) Avego Management, as the co-investment manager of Avego Fund, may be deemed to beneficially own the 243,563 Shares beneficially owned by Avego Fund; (viii) Velan Capital, as the investment manager of each of Velan Master and Velan Horizon and co-investment manager of Avego Fund, may be deemed to beneficially own the 3,363,347 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund; (ix) Velan IM GP, as the general partner of Velan Capital, may be deemed to beneficially own the 3,363,347 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund; (x) Mr. Morgan, as the Chief Investment Officer of Velan Capital and a Managing Member of each of Velan GP, Velan Horizon GP and Velan IM GP, may be deemed to beneficially own the 3,363,347 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund; (xi) Mr. Venkataraman, as the Managing Member of each of Avego GP and Avego Management and a Managing Member of each of Velan GP, Velan Horizon GP and Velan IM GP, may be deemed to beneficially own the 3,363,347 Shares beneficially owned in the aggregate by Velan Master, Velan Horizon and Avego Fund; and (xii) Mr. Kapoor directly beneficially owns 35,013 Shares, including 30,638 Shares underlying certain options. If the warrants owned by Velan Master and Velan Horizon were not subject to a 9.99% beneficial ownership blocker provision, the Reporting Persons would collectively beneficially own an aggregate of 3,918,775 Shares (including 1,234,567 Shares underlying the warrants and 30,638 Shares underlying certain options). The filing of this Schedule 13G shall not be construed as an admission that the Reporting Persons are, for purposes of Section 13(d) of the Exchange Act, the beneficial owners of any securities of the Issuer that he or it does not directly own. Each of the Reporting Persons specifically disclaims beneficial ownership of the securities reported herein that he or it does not directly own.

(b) Percent of class:

The following percentages are based on 33,274,561 Shares outstanding as of August 10, 2026, which is the total number of Shares outstanding as reported in the Issuer's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission on August 14, 2026, plus the Shares underlying the warrants that may be exercisable by the Reporting Persons, as applicable and subject to a 9.99% beneficial ownership blocker provision, and solely with respect to Mr. Kapoor, the Shares issuable upon the exercise of stock options that were awarded to him by the Issuer. As of the date hereof, (i) Velan Master beneficially owns approximately 8.9% of the outstanding Shares; (ii) Velan GP may be deemed to beneficially own approximately 8.9% of the outstanding Shares; (iii) Velan Horizon beneficially owns approximately 0.2% of the outstanding Shares; (iv) Velan Horizon GP may be deemed to beneficially own approximately 0.2% of the outstanding Shares; (v) Avego Fund beneficially owns approximately 0.7% of the outstanding Shares; (vi) Avego GP may be deemed to beneficially own approximately 0.7% of the outstanding Shares; (vii) Avego Management may be deemed to beneficially own approximately 0.7% of the outstanding Shares; (viii) Velan Capital may be deemed to beneficially own approximately 9.9% of the outstanding Shares; (ix) Velan IM GP may be deemed to beneficially own approximately 9.9% of the outstanding Shares; (x) Mr. Morgan may be deemed to beneficially own approximately 9.9% of the outstanding Shares; (xi) Mr. Venkataraman may be deemed to beneficially own approximately 9.9% of the outstanding Shares; and (xii) Mr. Kapoor beneficially owns approximately 0.1% of the outstanding Shares. If the warrants owned by Velan Master and Velan Horizon were not subject to a 9.99% beneficial ownership blocker provision, the Reporting Persons would collectively beneficially own an aggregate of approximately 11.3% of the outstanding Shares. %

(c) Number of shares as to which the person has:

(i) Sole power to vote or to direct the vote:

See Cover Pages Items 5-9.

(ii) Shared power to vote or to direct the vote:

See Cover Pages Items 5-9.

(iii) Sole power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

(iv) Shared power to dispose or to direct the disposition of:

See Cover Pages Items 5-9.

Item 5. Ownership of 5 Percent or Less of a Class.

Item 6. Ownership of more than 5 Percent on Behalf of Another Person.

Not Applicable

Item 7. Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.

Not Applicable

Item 8. Identification and Classification of Members of the Group.

If a group has filed this schedule pursuant to §240.13d-1(b)(1)(ii)(K), so indicate under Item 3(k) and attach an exhibit stating the identity and Item 3 classification of each member of the group. If a group has filed this schedule pursuant to §240.13d-1(c) or §240.13d-1(d), attach an exhibit stating the identity of each member of the group.

See Exhibit 99.1.

Item 9. Notice of Dissolution of Group.

Not Applicable

Item 10. Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under § 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

Velan Capital Master Fund LP

Signature:	/s/ Adam Morgan
Name/Title:	Adam Morgan, Managing Member of Velan Capital Holdings LLC, its General Partner
Date:	08/17/2026

Velan Capital Holdings LLC

Signature:	/s/ Adam Morgan
Name/Title:	Adam Morgan, Managing Member
Date:	08/17/2026

Velan Horizon Fund LP

Signature:	/s/ Adam Morgan
Name/Title:	Adam Morgan, Managing Member of Velan Horizon GP LLC, its General Partner
Date:	08/17/2026

Velan Horizon GP LLC

Signature: /s/ Adam Morgan
Name/Title: Adam Morgan, Managing Member
Date: 08/17/2026

Avego Healthcare Capital, L.P.

Signature: /s/ Balaji Venkataraman
Name/Title: Balaji Venkataraman, Managing Member of Avego Healthcare Capital Holdings, LLC, its General Partner
Date: 08/17/2026

Avego Healthcare Capital Holdings, LLC

Signature: /s/ Balaji Venkataraman
Name/Title: Balaji Venkataraman, Managing Member
Date: 08/17/2026

Avego Management LLC

Signature: /s/ Balaji Venkataraman
Name/Title: Balaji Venkataraman, Managing Member
Date: 08/17/2026

Velan Capital Investment Management LP

Signature: /s/ Adam Morgan
Name/Title: Adam Morgan, Managing Member of Velan Capital Management LLC, its General Partner
Date: 08/17/2026

Velan Capital Management LLC

Signature: /s/ Adam Morgan
Name/Title: Adam Morgan, Managing Member
Date: 08/17/2026

Morgan Adam

Signature: /s/ Adam Morgan
Name/Title: Adam Morgan
Date: 08/17/2026

VENKATARAMAN BALAJI

Signature: /s/ Balaji Venkataraman
Name/Title: Balaji Venkataraman
Date: 08/17/2026

Kapoor Vishal

Signature: /s/ Vishal Kapoor
Name/Title: Vishal Kapoor
Date: 08/17/2026

Exhibit Information

99.1 - Joint Filing Agreement

Exhibit 99.1

Joint Filing Agreement

The undersigned hereby agree that the Statement on Schedule 13G dated August 17, 2026 with respect to the Voting Common Stock, par value $0.0001 per share, of Jasper Therapeutics, Inc., and any amendments thereto executed by each and any of the undersigned shall be filed on behalf of each of the undersigned pursuant to and in accordance with the provisions of Rule 13d-1(k)(1) under the Securities Exchange Act of 1934, as amended.

Velan Capital Master Fund LP

By: /s/ Adam Morgan
Adam Morgan, Managing Member of Velan Capital Holdings LLC, its General Partner
Date: 08/17/2026

Velan Capital Holdings LLC

By: /s/ Adam Morgan
Adam Morgan, Managing Member
Date: 08/17/2026

Velan Horizon Fund LP

By: /s/ Adam Morgan
Adam Morgan, Managing Member of Velan Horizon GP LLC, its General Partner
Date: 08/17/2026

Velan Horizon GP LLC

By: /s/ Adam Morgan
Adam Morgan, Managing Member
Date: 08/17/2026

Avego Healthcare Capital, L.P.

By: /s/ Balaji Venkataraman
Balaji Venkataraman, Managing Member of Avego Healthcare Capital Holdings, LLC, its General Partner
Date: 08/17/2026

Avego Healthcare Capital Holdings, LLC

By: /s/ Balaji Venkataraman
Balaji Venkataraman, Managing Member
Date: 08/17/2026

Avego Management LLC

By: /s/ Balaji Venkataraman
Balaji Venkataraman, Managing Member
Date: 08/17/2026

Velan Capital Investment Management LP

By: /s/ Adam Morgan
Adam Morgan, Managing Member of Velan Capital Management LLC, its General Partner
Date: 08/17/2026

Velan Capital Management LLC

By: /s/ Adam Morgan
Adam Morgan, Managing Member
Date: 08/17/2026

Morgan Adam

By: /s/ Adam Morgan
Adam Morgan
Date: 08/17/2026

VENKATARAMAN BALAJI

By: /s/ Balaji Venkataraman
Balaji Venkataraman
Date: 08/17/2026

Kapoor Vishal

By: /s/ Vishal Kapoor
Vishal Kapoor
Date: 08/17/2026